Phase II Clinical Trial of Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma

Trial Profile

Phase II Clinical Trial of Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Sep 2017

At a glance

  • Drugs Bavituximab (Primary) ; Temozolomide
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Sep 2017 According to a Peregrine Pharmaceuticals media release, National Comprehensive Cancer Network (NCCN) is responsible for oversight and monitoring of this and other two clinical studies (CTP700276381 and CTP276389) through the research grant.
    • 07 Sep 2017 According to a National Comprehensive Cancer Network media release, first patient has been dosed.
    • 16 Jun 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top